Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03028103
Title Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Epizyme, Inc.
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

mantle cell lymphoma

Therapies

Fluconazole + Tazemetostat

Omeprazole + Repaglinide + Tazemetostat

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.